Therapeutic Asset Ratings

3,774 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD Lymphoma	Leland Metheny	P2	CCC (51)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Mixed Phenotype Acute Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P2	CCC (51)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Acute Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Hematopoietic And Lymphoid Cell Neoplasm	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Lymphoblastic Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Minimal Residual Disease	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Anti-Bcma Car-T Plasma Cell Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (51)
Anti-Cd19 Car T-Cells Large B-Cell Lymphoma	KK Women's and Children's Hospital	P2	CCC (51)
Autologous Hb-Admscs Traumatic Brain Injury	Hope Biosciences LLC	P2	CCC (51)
Brexucabtagene Autoleucel Large B-Cell Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
Breyanzi Injectable Product Large B-Cell Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (51)
cd19/cd22-bispecific car-t cells B-Cell Acute Lymphoblastic Leukemia	Beijing Tongren Hospital	P2	CCC (51)
cd19/cd22-bispecific car-t cells B-Cell Non-Hodgkin Lymphoma	Beijing Tongren Hospital	P2	CCC (51)
cd19/cd22-bispecific car-t cells Diffuse Large B-Cell Lymphoma	Beijing Tongren Hospital	P2	CCC (51)
cd19+cd22 car-t B-Cell Acute Lymphoblastic Leukemia	The First Affiliated Hospital of Soochow University	P2	CCC (51)
cd70.car nk cells Large B-Cell Lymphoma	M.D. Anderson Cancer Center	P2	CCC (51)
Cemacabtagene Ansegedleucel Large B-Cell Lymphoma	Allogene Therapeutics	P2	CCC (51)
Chimeric Antigen Receptor Modified T Cells Infusion Peripheral T Cell Lymphoma	UNC Lineberger Comprehensive Cancer Center	P2	CCC (51)
Dc-Cik Colorectal Neoplasms	The First People's Hospital of Changzhou	P2	CCC (51)
Dc-Cik Lymphoma, Non-Hodgkin	The First People's Hospital of Changzhou	P2	CCC (51)
Dendritic Cell Tumor Fusion Primary Peritoneal Cancer	Beth Israel Deaconess Medical Center	P2	CCC (51)
Dilanubicel Chronic Myeloid Leukemia	Fred Hutchinson Cancer Center	P2	CCC (51)
e7 tcr-t cells Metastatic Malignant Neoplasm	Christian Hinrichs	P2	CCC (51)
Ebx-102 Acute Leukemia Of Ambiguous Lineage	Imperial College London	P2	CCC (51)
Ebx-102 Chronic Myelomonocytic Leukemia	Imperial College London	P2	CCC (51)

Showing 476 to 500 of 3,774 assets

PreviousPage 20 of 151Next